End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
23.98
CNY
|
+0.13%
|
|
+6.63%
|
+4.85%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,993
|
11,142
|
12,993
|
13,628
|
-
|
-
|
Enterprise Value (EV)
1 |
13,993
|
11,142
|
12,993
|
13,628
|
13,628
|
13,628
|
P/E ratio
|
65.2
x
|
11
x
|
36.9
x
|
28.6
x
|
21.6
x
|
17.2
x
|
Yield
|
1.16%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11.9
x
|
-
|
6.33
x
|
5.99
x
|
4.88
x
|
3.93
x
|
EV / Revenue
|
11.9
x
|
-
|
6.33
x
|
5.99
x
|
4.88
x
|
3.93
x
|
EV / EBITDA
|
-
|
-
|
23.9
x
|
18.6
x
|
14
x
|
11.8
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
9.17
x
|
-
|
5.08
x
|
4.62
x
|
3.86
x
|
3.33
x
|
Nbr of stocks (in thousands)
|
567,000
|
567,000
|
568,129
|
568,308
|
-
|
-
|
Reference price
2 |
24.68
|
19.65
|
22.87
|
23.98
|
23.98
|
23.98
|
Announcement Date
|
2/18/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1,178
|
-
|
2,053
|
2,273
|
2,792
|
3,463
|
EBITDA
1 |
-
|
-
|
-
|
543.4
|
732.6
|
973.1
|
1,156
|
EBIT
1 |
-
|
226.8
|
-
|
340.5
|
524.5
|
699.6
|
836.5
|
Operating Margin
|
-
|
19.26%
|
-
|
16.59%
|
23.07%
|
25.05%
|
24.15%
|
Earnings before Tax (EBT)
1 |
-
|
227.8
|
-
|
330.1
|
521.1
|
695.2
|
831.7
|
Net income
1 |
210.5
|
204.7
|
-
|
358.4
|
476.3
|
630.3
|
792.6
|
Net margin
|
-
|
17.38%
|
-
|
17.46%
|
20.95%
|
22.57%
|
22.88%
|
EPS
2 |
0.4143
|
0.3786
|
1.780
|
0.6200
|
0.8375
|
1.108
|
1.397
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
0.2857
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/22/21
|
2/18/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
---|
Net sales
1 |
431.3
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
66.03
|
Net margin
|
15.31%
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
4/19/24
|
Fiscal Period: December |
2020
|
2021
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
17.2%
|
14.3%
|
15.4%
|
17.4%
|
18.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
9.46%
|
11.6%
|
13.7%
|
14.8%
|
Assets
1 |
-
|
-
|
3,789
|
4,106
|
4,600
|
5,355
|
Book Value Per Share
2 |
-
|
2.690
|
4.510
|
5.190
|
6.220
|
7.210
|
Cash Flow per Share
2 |
-
|
0.4600
|
-0.1300
|
1.210
|
1.250
|
1.550
|
Capex
1 |
-
|
373
|
663
|
410
|
370
|
477
|
Capex / Sales
|
-
|
31.64%
|
32.28%
|
18.04%
|
13.25%
|
13.78%
|
Announcement Date
|
4/22/21
|
2/18/22
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
23.98
CNY Average target price
28.67
CNY Spread / Average Target +19.55% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.85% | 1.88B | | +73.17% | 12.36B | | -20.70% | 7.83B | | +15.56% | 7.21B | | +4.77% | 5.97B | | +11.77% | 5.14B | | +29.65% | 4.43B | | -18.81% | 3.9B | | -41.99% | 2.2B | | +1.24% | 2.02B |
Medical Equipment
|